Showing results 1 - 10 of 23 for the search terms: HIV prevention.
GenVec, Inc. (Nasdaq: GNVC) announced that the company will present on GenVec’s malaria vaccine program at the American Society of Tropical Medicine and Hygiene (ASTMH) 57th Annual Meeting, which will take place in New Orleans, LA on December 7-11, 2008. Two presentations, highlighting research conducted in this program, will be given by GenVec scientists. Additional [...]
The Elizabeth Glaser Pediatric AIDS Foundation has completed the pilot phase of a home-based program in Uganda that teaches HIV-positive pregnant women how to administer the antiretroviral nevirapine to their infants immediately after birth to prevent mother-to-child transmission of the virus, New Vision reports. According to New Vision, the pediatric form of nevirapine can reduce [...]
Proactive measures can reduce hip fracture rates by an average of 37.2 percent — and as much as 50 percent — among those at risk, according to a study conducted by Kaiser Permanente Southern California. The study was published online on November 3 by The Journal of Bone & Joint Surgery, a peer-reviewed journal.
The largest [...]
A study conducted by Kaiser Permanente Southern California has shown that proactive measures can reduce hip fracture rates by an average of 37.2 percent — and as much as 50 percent — among those at risk. The study was published online on November 3 by The Journal of Bone & Joint Surgery, a peer-reviewed journal.
The [...]
Cure rates for certain groups of difficult-to-treat hepatitis C patients can be improved significantly by extending the treatment period with PEGASYS® (peginterferon alfa-2a (40KD)) and COPEGUS® (ribavirin) to 72 weeks, according to new studies being presented at AASLD this week in San Francisco.
“Seeking solutions for difficult-to-treat hepatitis C with the currently-available agents is a priority,” [...]
A new, independently-conducted study being presented at AASLD shows that PEGASYS® (peginterferon alfa-2a (40KD)) regimens result in higher cure rates for hepatitis C patients compared to regimens with another pegylated interferon.
Comparing Today’s Standard Treatment Regimens: The Milan Safety Tolerability Study
Prof. Colombo, Head of the 1st Division of Gastroenterology and A.M. Migliavacca Center for Liver Disease [...]
New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection. Tibotec will present findings from three TMC435 studies, including a late-breaker poster on the proof-of-principle phase IIa trial, OPERA-1 (TMC435-C201), at the American Association for the Study [...]
Gilead Sciences, Inc. (Nasdaq:GILD - News) today announced the presentation of two-year (96-week) data from two Phase III pivotal clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection. These data will be presented during oral sessions at [...]
A new, independently-conducted study being presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) shows that PEGASYS® (peginterferon alfa-2a) treatment regimens result in higher sustained virological response (SVR) rates for hepatitis C patients as compared to regimens with another pegylated interferon.
Comparing Today’s Standard Treatment Regimens: The Milan [...]
New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection. Tibotec will present findings from three TMC435 studies, including a late-breaker poster on the proof-of-principle phase IIa trial, OPERA-1 (TMC435-C201), at the American Association for the Study [...]
